Into the light? Diabetic nephropathy and vitamin D

被引：23
作者：
Thomas, Merlin C. [1 ,2 ]
Cooper, Mark E. [1 ]
机构：
[1] Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia
[2] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
来源：
LANCET | 2010年 / 376卷 / 9752期
关键词：
CHRONIC KIDNEY-DISEASE; PARICALCITOL; HEMODIALYSIS; TRIAL;
D O I：
10.1016/S0140-6736(10)61304-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1521 / 1522
页数：2
相关论文
共 13 条
  • [1] Antiproteinuric effect of oral paricalcitol in chronic kidney disease
    Agarwal, R
    Acharya, M
    Tian, J
    Hippensteel, RL
    Melnick, JZ
    Qiu, P
    Williams, L
    Batlle, D
    [J]. KIDNEY INTERNATIONAL, 2005, 68 (06) : 2823 - 2828
  • [2] Paricalcitol reduces albuminuria and inflammation in chronic kidney disease - A randomized double-blind pilot trial
    Alborzi, Pooneh
    Patel, Nina A.
    Peterson, Carla
    Bills, Jennifer E.
    Bekele, Dagim M.
    Bunaye, Zerihun
    Light, Robert P.
    Agarwal, Rajiv
    [J]. HYPERTENSION, 2008, 52 (02) : 249 - 255
  • [3] Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
    de Zeeuw, Dick
    Agarwal, Rajiv
    Amdahl, Michael
    Audhya, Paul
    Coyne, Daniel
    Garimella, Tushar
    Parving, Hans-Henrik
    Pritchett, Yili
    Remuzzi, Giuseppe
    Ritz, Eberhard
    Andress, Dennis
    [J]. LANCET, 2010, 376 (9752) : 1543 - 1551
  • [4] Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality
    Dusso, Adriana
    Arcidiacono, Maria Vittoria
    Yang, Jing
    Tokumoto, Masanori
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 121 (1-2) : 193 - 198
  • [5] Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial
    Fishbane, Steven
    Chittineni, Harini
    Packman, Michal
    Dutka, Paula
    Ali, Nicole
    Durie, Nicole
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (04) : 647 - 652
  • [6] Suppression of renin-angiotensin gene expression in the kidney by paricalcitol
    Freundlich, Michael
    Quiroz, Yasmir
    Zhang, Zhongyi
    Zhang, Yan
    Bravo, Yanauri
    Weisinger, Jose R.
    Li, Yan Chun
    Rodriguez-Iturbe, Bernardo
    [J]. KIDNEY INTERNATIONAL, 2008, 74 (11) : 1394 - 1402
  • [7] Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]
  • [8] The impact of diabetes mellitus on vitamin D metabolism in predialysis patients
    Tanaka, Hirotaka
    Hamano, Takayuki
    Fujii, Naohiko
    Tomida, Kodo
    Matsui, Isao
    Mikami, Satoshi
    Nagasawa, Yasuyuki
    Ito, Takahito
    Moriyama, Toshiki
    Horio, Masaru
    Imai, Enyu
    Isaka, Yoshitaka
    Rakugi, Hiromi
    [J]. BONE, 2009, 45 (05) : 949 - 955
  • [9] Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
    Teng, M
    Wolf, M
    Lowrie, E
    Ofsthun, N
    Lazarus, JM
    Thadhani, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) : 446 - 456
  • [10] Mortality risk among hemodialysis patients receiving different vitamin D analogs
    Tentori, F.
    Hunt, W. C.
    Stidley, C. A.
    Rohrscheib, M. R.
    Bedrick, E. J.
    Meyer, K. B.
    Johnson, H. K.
    Zager, P. G.
    [J]. KIDNEY INTERNATIONAL, 2006, 70 (10) : 1858 - 1865
12